Pfizer Reports Positive Results From Study Co-Administering Vaccines for Covid-19, Pneumococcal Disease
January 12 2022 - 6:37AM
Dow Jones News
By Matt Grossman
Pfizer Inc. said a Phase 3 study in which patients were
administered Covid-19 vaccines and the company's Prevnar vaccine
for pneumococcal disease at the same time led to positive top-line
results.
In the study, responses elicited by the Prevnar vaccine for
Covid-19 were similar whether or not the vaccine was given
alongside a Covid-19 vaccine. The same was true for Covid-19
vaccination. The safety profiles of the shots were little changed
compared with being administered separately, the company said.
Giving two vaccines at once could be a way to promote vaccine
update, Pfizer said.
"As the Covid-19 vaccines and booster doses continue to be
administered, we believe that healthcare providers have an
opportunity to talk to their adult patients about other recommended
vaccines in line with CDC guidance," the company said.
Pfizer created its Covid-19 vaccine alongside BioNTech SE.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
January 12, 2022 07:22 ET (12:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024